CAF®10b

Investigated by: Aurum Institute · Bill and Melinda Gates Foundation · Leiden University Medical Center · South African Tuberculosis Vaccine Initiative · Statens Serum Institut

today NCT06050356 · Ph 1

202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06050356	Mar 2024 → Dec 2026 expected	—	Statens Serum Institut	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	CAF10b	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06050356 ↗
Route	Intramuscular	“Participants will receive two i.m. injections of CAF®10b (full adjuvant dose) on Day 1 and Day 29” NCT06050356 ↗